Prediction of Kirsten rat sarcoma (<i>KRAS</i>) mutation in rectal cancer with amide proton transfer-weighted magnetic resonance imaging.

ABSTRACT:

Background

Kirsten rat sarcoma (KRAS) mutation drives resistance to anti-epidermal growth factor receptor (anti-EGFR)-targeted therapies in rectal cancer. Amide proton transfer-weighted magnetic resonance imaging (APTw MRI) might be a supplement to the evaluation of KRAS mutation because the APTw value can reflect mobile cellular protein content in vivo. This study aimed to determine whether APTw MRI could predict KRAS mutation in rectal cancer and compare this technique with diffusion-weighted imaging (DWI).

Methods

This retrospective study reviewed 153 consecutive patients with rectal cancer from April 2019 to June 2021 in our hospital. Among them, a total of 55 patients who did not undergo neoadjuvant chemoradiotherapy and underwent preoperativ

SUBMITTER: Yang X 

PROVIDER: S-EPMC11485380 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature